Risk Factors for Fluconazole-Resistant Candidemia
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Previous studies have sought to determine the risk factors associated with candidemia caused by non- albicans Candida spp. or with potentially fluconazole-resistant Candida spp. ( C. glabrata and C. krusei ). Non- albicans Candida strains are a heterogeneous group that includes species with different levels of virulence, and only a limited number of C. glabrata isolates are resistant to fluconazole. We set out to identify the risk factors associated with microbiologically proven fluconazole-resistant candidemia. A prospective study including adult patients with candidemia was performed. Data were collected on patient demographics; underlying diseases; exposure to corticosteroids, antibiotics, or fluconazole; and invasive procedures. Risk factors associated either with non- albicans Candida spp. or potentially fluconazole-resistant Candida spp. ( C. glabrata or C. krusei ) or with Candida spp. with microbiologically confirmed fluconazole resistance were assessed using logistic regressions. We included 226 candidemia episodes. Non- albicans Candida isolates accounted for 53.1% of the fungal isolates, but only 18.2% of the cases were caused by potentially fluconazole-resistant organisms. Thirty isolates exhibited microbiologically confirmed fluconazole resistance. The multivariate analysis revealed that independent predictors associated with fluconazole-resistant Candida spp. were neutropenia (odds ratio [OR] = 4.94; 95% confidence interval [CI] = 1.50 to 16.20; P = 0.008), chronic renal disease (OR = 4.82; 95% CI = 1.47 to 15.88; P = 0.01), and previous fluconazole exposure (OR = 5.09; 95% CI = 1.66 to 15.6; P = 0.004). Independently significant variables associated with non- albicans Candida bloodstream infection or with potentially fluconazole-resistant Candida spp. did not include previous fluconazole exposure. We concluded that prior fluconazole treatment is an independent risk factor only for candidemia caused by microbiologically confirmed fluconazole resistant species. Our findings may be of value for selecting empirical antifungal therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191 · cited 1×
“Fluconazole is currently considered the initial therapy for most adult patients with candidemia (20).”
BackgroundAttributable mortality of candidemia: a systematic review of matched cohort and case-control studies
Falagas, M. E., Apostolou, K. E., & Pappas, V. D. (2006) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-006-0159-2 · Cited by 294 · cited 2×
“812 Median (p25, p75) LOS (days) before candidemia 21 (11, 35) 17 (6, 32) 0.”
BackgroundEmpirical Fluconazole versus Placebo for Intensive Care Unit Patients: A Randomized Trial
Schuster, M. G., Edwards, J. E., Sobel, J. D., Darouiche, R. O., Karchmer, A. W., Hadley, S., Slotman, G., Panzer, H., Biswas, P., & Rex, J. H. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-2-200807150-00004 · Cited by 210
Dimopoulos, G., Ntziora, F., Rachiotis, G., Armaganidis, A., & Falagas, M. E. (2008) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e3181607262 · Cited by 189 · cited 4×
“(1, 9, 10, 23) or by potentially fluconazole-resistant organisms (Candida glabrata and Candida krusei) (16, 23, 28) but have not taken into consideration in vitro resistance to fluconazole.”
BackgroundInfluentialTreatment-related risk factors for hospital mortality in Candida bloodstream infections
Labelle, A. J., Micek, S. T., Roubinian, N., & Kollef, M. H. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e31818b3477 · Cited by 181 · cited 3×
“Moreover, a low fluconazole dosage in the empirical regimen is associated with increased hospital mortality in patients with Candida bloodstream infections (14).”
BackgroundDavis, S. L., Vazquez, J. A., & Mckinnon, P. S. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1h516 · Cited by 71
Cited by
T2 Magnetic Resonance Assay for the Rapid Diagnosis of Candidemia in Whole Blood: A Clinical Trial
Mylonakis, E., Clancy, C. J., Ostrosky-Zeichner, L., Garey, K. W., Alangaden, G. J., Vazquez, J. A., Groeger, J. S., Judson, M. A., Vinagre, Y.-M., Heard, S. O., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/ciu959 · Cited by 443
Antifungal drug resistance among Candida species: mechanisms and clinical impact
Sanguinetti, M., Posteraro, B., & Lass‐Flörl, C. (2015) · Mycoses · doi:10.1111/myc.12330 · Cited by 394
Pfaller, M., Neofytos, D., Diekema, D., Azie, N., Meier-Kriesche, H.-U., Quan, S.-P., & Horn, D. (2012) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.10.003 · Cited by 394
The Changing Epidemiology of Invasive Fungal Infections
Enoch, D. A., Yang, H., Aliyu, S. H., & Micallef, C. (2017) · Methods in Molecular Biology · doi:10.1007/978-1-4939-6515-1_2 · Cited by 370
Cleveland, A. A., Farley, M. M., Harrison, L. H., Stein, B., Hollick, R., Lockhart, S. R., Magill, S. S., Derado, G., Park, B. J., & Chiller, T. M. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis697 · Cited by 366
“Over the past decade, Candida species with reduced fluconazole susceptibility, such as Candida glabrata, have become more prevalent in some patient populations [8–12].”
Metadata
- Authors
- Garnacho-Montero, J., Díaz-Martín, A., García-Cabrera, E., Ruiz Pérez de Pipaón, M., Hernández-Caballero, C., Aznar-Martín, J., Cisneros, J. M., & Ortiz-Leyba, C.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2010-08
- Volume
- 54
- Issue
- 8
- Pages
- 3149-3154
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2101234999
- Cited by
- 127
- References
- 6
- FWCI
- 6.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risk Factors for Fluconazole-Resistant Candidemia. https://app.cochat.ai/papers/10.1128/aac.00479-10
- The paper
- Garnacho-Montero, J., Díaz-Martín, A., García-Cabrera, E., Ruiz Pérez de Pipaón, M., Hernández-Caballero, C., Aznar-Martín, J., Cisneros, J. M., & Ortiz-Leyba, C. (2010). Risk Factors for Fluconazole-Resistant Candidemia. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00479-10
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.